Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nastech Partners With Merck On Phase I Obesity Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Nastech cites Merck’s demonstrated urgency to enter the class and its R&D capabilities as a reason to collaborate on the nasal spray agent earlier than planned and before it has completed Phase II trials. Merck would be primarily responsible for worldwide research, regulatory approvals, sales and marketing.

You may also be interested in...



Merck Drops Nastech’s Nasal Spray

Merck terminated a partnership March 1 to jointly develop Nastech's Phase I peptide YY3-36 nasal spray for treatment of obesity after concluding from a preliminary proof of concept study that it did not demonstrate efficacy

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel